Cognitive processes of apathy in Huntington's disease show high sensitivity to disease progression.
Clinical Parkinsonism & Related Disorders(2022)
摘要
Background:Disease-modifying treatments for Huntington's disease (HD) are entering clinical trials: there is a pressing need for objective outcome measures of disease progression. Our previous work showed an association between 2 novel, objective cognitive tasks and apathy - a core feature of disease progression in HD.
Objective:Evaluate the longitudinal validity and sensitivity of the novel Persistence and Maze tasks to assess their utility as clinical outcome measures in HD.
Methods:83 participants positive for the HD gene and 54 controls performed a battery of established and novel tools, at baseline and 12 month follow up.
Results:The Maze task was found to be the most sensitive measure of change at 12 months, including the current gold-standard measure (the composite disease progression score).
Conclusion:The Maze task has potential as a novel outcome measure of disease progression in HD and may have utility in other major neurodegenerative diseases.
更多查看译文
关键词
Biomarker,Clinical trials,Cognition,Huntington’s Disease,Neuropsychiatry
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要